GLAUKOS Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Glaukos (GKOS) officer Tomas Navratil plans to sell 1,457 shares of common stock, tied to restricted stock vesting events in March 2025. The sale is part of a Rule 144 notice, with prior sales also reported. The shares are part of Navratil's compensation.
Glaukos Corp (GKOS) shares fell 5.2% to $170.38, within a 52-week range of $73.16 to $191.62. The stock is up 94.7% year-to-date but has declined 5.5% in the past week and 6.1% in the past month. GuruFocus values GKOS at $151.61, suggesting it is 12.4% overvalued. The company has a GF Score of 77/100, indicating above-average performance. Insiders sold $67.6M in shares over the past year with no buying.
Glaukos (GKOS) shares fell 5.2% due to investor concerns over reimbursement delays for key products, as discussed at a healthcare conference. Management noted ongoing hurdles despite expanding coverage. Recent insider sales and broader market weakness also contributed to the decline. The company reported strong Q2 sales growth but remains in investment mode, making it sensitive to commercialization pace commentary.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning GKOS (GLAUKOS Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent GKOS coverage spans financial news, earnings and insider activity.
In the last 30 days, GKOS insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($2.7M). The most active reporter was Navratil Tomas, CHIEF DEVELOPMENT OFFICER, with 10 filings. 70% of those filings were made under pre-arranged Rule 10b5-1 plans.
The disclosed sale may create modest selling pressure on GKOS.
The price drop and insider selling suggest short‑term weakness.
Insider sell-off and cautious conference comments likely pressure the stock lower.
Insider sale may signal reduced confidence, potential short-term pressure on the stock.
Insider sale may indicate reduced confidence or liquidity need, potentially pressuring the stock.
AlphAI scores every news story that mentions GKOS with an AI model for sentiment and relevance, and aggregates insider trades from GLAUKOS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Glaukos (GKOS) officer Tomas Navratil plans to sell 1,457 shares of common stock, tied to restricted stock vesting events in March 2025. The sale is part of a Rule 144 notice, with prior sales also reported. The shares are part of Navratil's compensation.
1 min readGlaukos Corp (GKOS) shares fell 5.2% to $170.38, within a 52-week range of $73.16 to $191.62. The stock is up 94.7% year-to-date but has declined 5.5% in the past week and 6.1% in the past month. GuruFocus values GKOS at $151.61, suggesting it is 12.4% overvalued. The company has a GF Score of 77/100, indicating above-average performance. Insiders sold $67.6M in shares over the past year with no buying.
2 min readGlaukos (GKOS) shares fell 5.2% due to investor concerns over reimbursement delays for key products, as discussed at a healthcare conference. Management noted ongoing hurdles despite expanding coverage. Recent insider sales and broader market weakness also contributed to the decline. The company reported strong Q2 sales growth but remains in investment mode, making it sensitive to commercialization pace commentary.
2 min readGlaukos Corp's (GKOS) Chief Development Officer, Tomas Navratil, sold 13,744 shares worth $2.48m on August 28, 2026. Shares sold ranged from $179.69 to $182.50. GKOS stock is up 88% over the past year but has recently pulled back. Navratil now owns 73,890 shares. Glaukos reported Q2 2026 revenue of $185.6m, up 50% YoY, and raised its full-year sales outlook. Analysts have raised price targets, with Truist Securities setting a target of $215.
1 min readNavratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 13,744 shares of GLAUKOS Corp (GKOS) at an average of $180.67 ($180.25–$182.50, $2.48M total) across 3 trades on 2026-08-28.
1 min readGlaukos (GKOS) officer Tomas Navratil filed a notice to sell 13,744 shares, valued at $2.48 million, under Rule 144. This follows prior sales of 1,537 and 716 shares in June and July 2026, respectively.
1 min readGlaukos (GKOS) shares rose 8% since its last earnings report, beating estimates with Q2 revenue of $185.6M (up 50% YoY) and narrowed losses. Growth was driven by iDose TR adoption and expanded guidance to $680M-$700M for 2026. The company has no debt and $286.2M in cash. Analysts have raised estimates, with a Zacks Rank #3 (Hold).
3 min readGlaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.
2 min readKliman Gilbert H sold 2,500 shares of GLAUKOS Corp (GKOS) at $190.00 ($0.48M total) on 2026-08-19.
1 min readGlaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.
2 min read
